X @Bloomberg
Bloomberg·2026-02-09 14:03
Under new drug-review rules, decisions at the FDA risk becoming more opaque, arbitrary or even politically motivated—making it far harder for pharma companies and their investors to model and plan https://t.co/UIkuRfRZNW ...